It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diabetic kidney disease (DKD), also known as diabetic nephropathy, is the leading cause of renal impairment and end-stage renal disease. Patients with diabetes are at risk for DKD because of poor control of their blood glucose, as well as nonmodifiable risk factors including age, ethnicity, and genetics. This genome-wide association study (GWAS) was conducted for the first time in the Emirati population to investigate possible genetic factors associated with the development and progression of DKD. We included data on 7,921,925 single nucleotide polymorphism (SNPs) in 258 cases of type 2 diabetes mellitus (T2DM) who developed DKD and 938 control subjects with T2DM who did not develop DKD. GWAS suggestive results (P < 1 × 10–5) were further replicated using summary statistics from three cohorts with T2DM-induced DKD (Bio Bank Japan data, UK Biobank, and FinnGen Project data) and T1DM-induced DKD (UK-ROI cohort data from Belfast, UK). When conducting a multiple linear regression model for gene-set analyses, the CNR2 gene demonstrated genome-wide significance at 1.46 × 10–6. SNPs in CNR2 gene, encodes cannabinoid receptor 2 or CB2, were replicated in Japanese samples with the leading SNP rs2501391 showing a Pcombined = 9.3 × 10–7, and odds ratio = 0.67 in association with DKD associated with T2DM, but not with T1DM, without any significant association with T2DM itself. The allele frequencies of our cohort and those of the replication cohorts were in most cases markedly different. In addition, we replicated the association between rs1564939 in the GLRA3 gene and DKD in T2DM (P = 0.016, odds ratio = 0.54 per allele C). Our findings suggest evidence that cannabinoid signalling may be involved in the development of DKD through CB2, which is expressed in different kidney regions and known to be involved in insulin resistance, inflammation, and the development of kidney fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Khalifa University, Center for Biotechnology, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729); Khalifa University, Department of Biology, College of Arts and Sciences, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729)
2 Khalifa University, Center for Biotechnology, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729)
3 Imperial College of London Diabetes Centre, Abu Dhabi, United Arab Emirates (GRID:grid.488461.7) (ISNI:0000 0004 4689 699X)
4 Queen’s University of Belfast, Centre for Public Health, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
5 Khalifa University, Center for Biotechnology, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729); Khalifa University, Department of Biomedical Engineering, College of Engineering, Abu Dhabi, United Arab Emirates (GRID:grid.440568.b) (ISNI:0000 0004 1762 9729)